Capstan Medical develops catheter-based heart valve replacement solutions that use surgical robotics to guide valve implants through small blood vessels, avoiding open-heart surgery. Its system combines implants, delivery catheters, and robotic navigation to treat mitral and tricuspid valve disease with minimally invasive methods. The company differentiates itself by integrating robotic guidance with catheter delivery and by pursuing less invasive replacements for structural heart disease, evidenced by the world’s first robotic-catheter mitral valve replacement in humans. Its goal is to provide safer, quicker-recovery treatments for patients with valve disease.
Company Size
51-200
Company Stage
Series C
Total Funding
$141.4M
Headquarters
Santa Cruz, California
Founded
2020
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?